Biggest News Aggregation in the World
๐Ÿ“ฐ Pluripotent Stem News

Pluripotent Stem News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Pluripotent Stem. Real-time updates on events, politics, business and more.

Clinical Trials Using iPSCs for Heart Diseases, Stroke, and Cancer Treatment Propel Induced Pluripotent Stem Cell Market Growth

Induced Pluripotent Stem Cell ((iPSC) Market Induced Pluripotent Stem Cell ((iPSC) Market Dublin, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at a CAGR of 6.9% over the analysis pe...
Nova Scotia United States Holdings Corporation Cell Signaling Technology Inc Drug Development Application To Witness Considerable Growth Stem Cell Research Funding
Source: yahoo.com

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology - CytoMed Therapeutics (NASDAQ:GDTC)

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary
Peter Choo Cytomed Therapeutics Limited China National Intellectual Property Administration Cytomed Therapeutics Agency For Science Generating Mimetic Innate Immune Cells

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).
Peter Choo Cytomed Therapeutics Limited Cytomed Therapeutics Exchange Commission Agency For Science Generating Mimetic Innate Immune Cells
Source: yahoo.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science